Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy in Children (PACTG 338)

DSpace/Manakin Repository

Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy in Children (PACTG 338)

Citable link to this page

. . . . . .

Title: Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy in Children (PACTG 338)
Author: Fiscus, Susan A; Kovacs, Andrea; Petch, Leslie A; Hu, Chengcheng; Wiznia, Andrew A; Mofenson, Lynne M; Yogev, Ram; Pelton, Stephen I; Napravnik, Sonia; Nachman, Sharon A; McIntosh, Kenneth; Stanley, Kenneth Earl

Note: Order does not necessarily reflect citation order of authors.

Citation: Fiscus, Susan A, Andrea Kovacs, Leslie A Petch, Chengcheng Hu, Andrew A Wiznia, Lynne M Mofenson, Ram Yogev, Kenneth McIntosh, Stephen I Pelton, Sonia Napravnik, Kenneth Stanley, and Sharon A Nachman. 2007. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Research and Therapy 4: 2.
Full Text & Related Files:
Abstract: Background: The association between baseline drug resistance mutations and subsequent increase in viral failure has not been established for HIV-infected children. We evaluated drug resistance mutations at 39 codon sites (21 protease inhibitor (PI) resistant codons and 18 nucleoside reverse transcriptase inhibitor (NRTI) resistant codons) for 92 clinically stable NRTI-experienced, PI-naive HIV-infected children 2 to 17 years of age who were initiating new therapy with ritonavir plus zidovudine (ZDV) and lamivudine or plus stavudine. The association between baseline drug resistance mutations and subsequent viral failure after 12 and 24 weeks of highly active antiretroviral therapy (HAART) was studied. Results: There were few primary PI associated mutations in this PI-naïve population, but 84% had NRTI mutations – codons 215 (66%), 41 (42%), 67 (37%), 210 (33%) and 70 (32%). None of the specific baseline drug resistance mutations were associated with a higher rate of virologic failure after 12 or 24 weeks of HAART. Median week 12 viral load decreased as the total number of NRTI mutations at baseline increased (P = 0.006). Specifically, a higher level of baseline ZDV resistance mutation was associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART regimen (P = 0.017). Conclusion: No increase was seen in the rate of viral failure after HAART associated with the presence of resistance mutations at baseline. This paradoxical result may be due to adherence, replicative capacity, or ZDV hypersusceptibility to the new regimen.
Published Version: doi://10.1186/1742-6405-4-2
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1802955/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:7349730

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters